Clinical Trials Logo

Clinical Trial Summary

Pts with histologically confirmed CRLM and whose CRS >2 were enrolled into this single-arm, phase II study. The critical enrollment criteria were that Subjects had completely resected Primary lesion and liver metastases and had no evidence of extrahepatic disease. After hepatectomy, HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2) was given every 4-6 weeks for 2-4 cycles depending on pts' health status, in combination with Sintilimab (200mg, iv, d1) and regorafenib (80mg, po, d1-21) every 3 weeks for up to 6 months. The primary endpoint was 1-year recurrence-free survival (RFS) and secondary endpoints included RFS, overall survival (OS), safety, and health-related quality of life.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05753163
Study type Interventional
Source Fudan University
Contact Lu Wang, M.D.
Phone +86-18121299357
Email sysucczyf@163.com
Status Recruiting
Phase Phase 2
Start date August 2, 2022
Completion date March 2025

See also
  Status Clinical Trial Phase
Recruiting NCT02642978 - Robot-assisted Procedure Versus Open Simultaneous Resection of Colorectal Cancer With Liver Metastases N/A
Active, not recruiting NCT02399995 - Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time
Active, not recruiting NCT04751773 - Postoperative Exercise Training in Patients With Colorectal Liver Metastases Undergoing Surgery (ELMA) N/A
Recruiting NCT03895723 - Minimally Invasive Versus Open Liver Resection for Patients With Colorectal Cancer Liver Metastases N/A
Completed NCT01523353 - Prehabilitation in Liver Surgery Phase 1
Recruiting NCT04678583 - Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer N/A
Completed NCT02727179 - Open vs Laparoscopic Liver Surgery for Colorectal Liver Metastases N/A